



COLLABORATIVE STAGE
DATA COLLECTION SYSTEM

Melanoma Carcinoma of the Skin

Education & Training Team
Collaborative Stage Data Collection System
Version 2



COLLABORATIVE STAGE
DATA COLLECTION SYSTEM

Melanoma

Learning Objectives

- Learn the differences between CSv1 and CSv2
- Be able to correctly abstract and stage a melanoma patient's chart



Deriving Stage

CSv1

code	definition	6th ed.
10	a-e	T1

CSv2

code	definition	7th ed.	6th ed.
110	a-c	T1a	T1
120	d-e	T1b	T1

4



Overview

- Changes from CSv1 to CSv2
- CS Tumor Size and Extension
- CS Lymph Nodes
- CS Mets at Dx
- Site Specific Factors

5



CS Tumor Size

- 001-988 001-988 mm (exact size in mm)
- 989 989 mm or larger
- 990 Micro focus or foci, no size of focus given
- 991 Described as <1 cm
- 992 <2 cm or >1 cm or between 1-2 cm
T1 NOS with no documentation of tumor size

6



CS Tumor Size

- 993 <3 cm or >2 cm or between 2-3 cm
T2 NOS with no documentation of tumor size
- 994 <4 cm or >3 cm or between 3-4 cm
- 995 <5 cm or >4 cm or between 4-5 cm

- CS Tumor Size Eval unchanged

7



CS Extension

- 000 In situ, non-invasive, intradermal, Clark level I
- 100 Papillary dermis invaded, Clark level II
- 200 Papillary-reticular dermal interface invaded,
Clark level III
- 300 Reticular dermis invaded, Clark level IV
- 400 Skin/dermis NOS, Localized NOS
- 500 SubQ tissue invaded, Clark level V

8



CS Extension

- 800 Further contiguous extension,
Underlying cartilage, bone, skeletal muscle
- 950 No evidence of primary tumor
- 999 Unknown extension, Primary tumor cannot
be assessed (e.g. shave biopsy or regressed
melanoma)

- CS Tumor Size/Extension Eval unchanged

9



CS Lymph Nodes

- 100 Regional nodes by primary site
- 120 Head and neck nodes
- 130 Satellite nodules or in-transit mets NOS (distance from primary site not stated) WITHOUT regional node involvement or regional node involvement not stated

10



CS Lymph Nodes

- 140 Satellite nodule(s) or in-transit mets ≤ 2 cm from primary WITHOUT regional node involvement or node involvement not stated
- 150 Satellite nodule(s) or in-transit mets >2 cm from primary WITHOUT regional node involvement or involvement not stated

11



CS Lymph Nodes

- 170 Matted nodes in code 100
- 180 Matted nodes in code 120
- 200 Satellite nodule(s) or in-transit mets WITH regional nodes in code 100
- 220 Satellite nodule(s) or in-transit mets WITH regional nodes in code 120
- 800 Lymph nodes NOS

12



MX Eliminated

- MX has been eliminated from 7th Edition
 - Clinical M0
 - Unless clinical or pathologic evidence of mets
- cM only requires history and physical
- Infer cM0 unless known cM1

13



CS Mets at Dx

- 05 Underlying cartilage, bone, skeletal muscle
- 10 Distant lymph nodes
- 40 Distant metastasis NOS
- 42 Mets to skin or subQ tissue beyond regional nodes
- 43 Lung

14



CS Mets at Dx

- 44 All other visceral sites
 - Carcinomatosis
 - Other distant sites
- 52 10 + 42
- 53 10 + 43
- 54 10 + 44

15



Mets at Dx-Metastatic Sites

- 4 new fields
 - Bone excluding marrow
 - Lung excluding pleura and pleural fluid
 - Brain excluding spinal cord and other CNS
 - Liver
- Code 0 when CS Mets at Dx is 00
- Code structure
 - 0 – No
 - 1 – Yes
 - 8 – Not applicable
 - 9 – Unknown

16



SSF1-3 Unchanged

- SSF1 Depth of Invasion
 - Code exact size in hundredths of mm
- SSF2 Ulceration
 - No mention of ulceration in path report – assume no ulceration
- SSF3 Clinical Status of Lymph Node Mets
 - Code 000 No lymph node mets OR
 - Code 000 Satellite lesion or in-transit mets without nodes

17



SSF4 LDH

- 000 Test not done
- 002 Within normal limits
- 004 Range 1 1.5 x normal limit OR elevated NOS
- 005 Range 2 1.5 – 10 x normal limit
- 006 Range 3 more than 10 normal limit
- 008 Test ordered, results not in chart

18



SSF5 LDH Value

- Code value of LDH
 - Prior to treatment or within 6 weeks of diagnosis
 - Give priority to the earliest tests performed
- Code value from same test used in SSF 4
- Record actual value for values 001 through 800
- Record range for values 801 and greater
 - Codes 801 – 825 are ranges in intervals of 20
 - Codes 826 – 863 are ranges in intervals of 50
 - Codes 864 - 921 are ranges in intervals of 100
 - Code 922 is a value of 10001 or greater

19



SSF5 LDH Value

- | Code | Description |
|-------|---|
| • 060 | Actual value of 60 |
| • 801 | Value 801 to 820 |
| • 864 | Value 3201 to 3300 |
| • 899 | Value 7701 to 7800 |
| • 922 | Value is 10001 or greater |
| • 995 | Stated as within normal limits, no other info |
| • 996 | Stated as elevated, no other info |
| • 997 | Test ordered, results not in chart |
| • 998 | Test not done |

20



SSF6 LDH Upper Limits of Normal

- Record upper limits of normal for LDH
- Upper limit of normal varies based on the lab
- 001-979 Upper limit of normal is 001-979
- 997 Upper limit of normal not in chart
- 998 Test not done
- 999 Unknown, no documentation

21



SSF7 Primary Tumor Mitotic Count/Rate

- 000 Mitotic rate <1 per millimeter squared
- 001-010 1-10 per millimeter squared
- 011 11 millimeter squared or greater
- 998 No histologic exam of primary site
- 999 Unknown, not stated, not documented

22



SSF8 Primary Tumor Regression

- Not identified should be coded as absent
- 000 No regression
Regression not identified
Regression absent
- 001 Regression present
- 999 Unknown, not stated, not documented

23



SSF9 Vertical Growth Phase

- Not identified should be coded as absent
- 000 No vertical growth phase present
Vertical growth phase not identified
Vertical growth phase absent
- 001 Vertical growth phase present
- 999 Unknown, not stated, not documented

24



Melanoma

- Addition of 5 new site specific factors
- T category is now based on
 - Depth of invasion
 - Ulceration
 - Mitotic rate

25



Inquiry & Response System

- Submit questions to Inquiry & Response System
 - Allows tracking for educational purposes
 - Provides information for all
- <http://web.facs.org/coc/default.htm>



26



Questions?



27



American Joint Committee on Cancer
Contact Information

Karen A. Pollitt – Manager

email: kpollitt@facs.org

phone: 312-202-5313

Donna M. Gress, RHIT, CTR – Technical Specialist

email: dgress@facs.org

phone: 312-202-5410

General Inquiries can be directed to AJCC@facs.org

AJCC Web Site

www.cancerstaging.org



28



COLLABORATIVE STAGING
DATA COLLECTION SYSTEM

Carcinoma of the Skin

Learning Objectives

- Learn the inclusions and exclusions for reportability
- Become familiar with CSv2 codes including new SSF codes



30

Overview

- Few changes from CS version 1
- CSv2 uses list of histology inclusions
- 5 new Site Specific Factors

31



CS Tumor Size

- 000 No mass/tumor found
- 001-988 001 – 988 mm (code exact size)
- 989 989 mm or larger
- 990 Micro focus or foci & no size of focus given
- 991 Describes as <1 cm

32



CS Tumor Size

- 992 Described as <2 cm or >1 cm or between 1-2 cm, Stated as T1 with no other info
- 993 Described as <3 cm or >2 cm or between 2-3 cm
- 994 Described as <4 cm or >3 cm or between 3-4 cm
- 995 Described as <5 cm or >4 cm or between 4-5 cm
- 999 Unknown, no size stated

33



CS Extension

- 000 In situ, non-invasive, Bowen's disease
- 100 Lesion confined to dermis
- 400 Localized NOS
- 500 SubQ tissue (through entire dermis)
- 510 Stated as T1
- 520 Stated as T2

34



CS Extension

- 550 Underlying cartilage and/or skeletal muscle
- 600 For skin of head and neck primaries only:
Maxilla, mandible, orbital bone, temporal bone
Stated as T3
- 710 For skin of head and neck primaries only:
Direct or perineural invasion of skull base
- 750 Bone (other than in code 600 or 710)

35



CS Extension

- 800 Further contiguous extension
- 810 Stated as T4
- 950 No evidence of primary tumor
- 999 Unknown, not documented

36



CS Lymph Nodes

- 000 No regional node involvement
- 150 Single ipsilateral node by primary site
- 160 Single ipsilateral node for some head & neck
- 180 Stated as N1
- 190 Stated as N2a

37



CS Lymph Nodes

- 250 Multiple ipsilateral nodes listed in code 150
- 260 Multiple ipsilateral nodes listed in code 160
- 290 Stated as N2b
- 350 Ipsilateral nodes listed in code 150, not stated single or multiple
- 360 Ipsilateral nodes listed in code 160, not stated single or multiple

38



CS Lymph Nodes

- 450 Bilat or contralateral nodes in code 150
- 460 Bilat or contralateral nodes in code 160
- 490 Stated as N2c

39



CS Lymph Nodes

- 550 Regional nodes listed in code 150, not stated: ipsilat/bilat/contralat AND single or multiple
- 560 Regional nodes listed in code 160, not stated: ipsilat/bilat/contralat AND single or multiple
- 600 Stated as N2 NOS
- 700 Stated as N3
- 800 Lymph nodes NOS

40



MX Eliminated

- MX has been eliminated from 7th Edition
 - Clinical M0
 - Unless clinical or pathologic evidence of mets
- cM only requires history and physical
- Infer cM0 unless known cM1

41



CS Mets at Dx

- 00 None
- 10 Distant lymph node(s)
- 40 Distant mets except distant nodes
Carcinomatosis
- 50 10 + 40
- 60 Distant mets NOS
Stated as M1

42



Mets at Dx-Metastatic Sites

- 4 new fields
 - Bone excluding marrow
 - Lung excluding pleura and pleural fluid
 - Brain excluding spinal cord and other CNS
 - Liver
- Code 0 when CS Mets at Dx is 00
- Code structure
 - 0 – No
 - 1 – Yes
 - 8 – Not applicable
 - 9 – Unknown

43



SSF1 Measured Thickness (Depth)

- Measurement in hundredths of mm
- 000 No mass or tumor found
- 001-979 0.01 – 9.79 mm
- 980 9.8 mm or larger
- 990 Microinvasion, microscopic focus or foci only and no depth given
- 998 No histologic exam of primary site
- 999 Not documented, unknown

44



SSF2 Clark Level

- 010 Clark level I: in situ; non-invasive
- 020 Clark level II papillary dermis invaded
- 030 Clark level III: papillary-reticular dermal interface invaded
- 040 Clark level IV: reticular dermis invaded
- 050 Clark level V: subQ tissue invaded (through entire dermis)

45



SSF3 Perineural Invasion

- 000 Perineural invasion not present, not identified
- 010 Perineural invasion present
- 998 No histologic exam of primary site
- 999 Unknown, cannot be assessed, no documentation

46



SSF4 High Risk Features

- Risk features
 - Poor differentiation (grade 3 or 4)
 - Depth \geq 4 mm depth
 - Clark level IV or V
 - Perineural invasion
 - Lymphovascular invasion
 - Primary of skin of ear (C44.2) or
 - Primary site of skin of hair-bearing (non-glabrous) skin of lip (C44.0)
- Several high risk features can upgrade T category
 - Count & code number of high risk features

47



SSF4 High Risk Features

- 010 1 risk feature
- 020 2 risk features
- 030 3 risk features
- 040 4 risk features
- 050 5 risk features
- 060 6 risk features

48



SSF5 Size of Lymph Nodes

- 000 No involved regional nodes
- 001-979 Exact size in millimeters
- 990 Micro focus or foci only, no size of focus given
- 991 Described as <1 mm

49



SSF5 Size of Lymph Nodes

- 992 Described as <2 cm or >1 cm or between 1-2 cm
- 993 Described as <3 cm or >2 cm or between 2-3 cm
- 994 Described as <4 cm or >3 cm or between 3-4 cm
- 995 Described as <5 cm or >4 cm or between 4-5 cm

50



SSF5 Size of Lymph Nodes

- 996 Described as <6 cm or >5 cm or between 5-6 cm
- 997 Described as >6 cm
- 999 Regional nodes involved, size not stated
Unknown if regional nodes involved
Not documented in chart

51



Carcinoma of the Skin

- 5 new site specific factors
- SSF4 high risk features can upgrade the T category

52



Inquiry & Response System

- Submit questions to Inquiry & Response System
 - Allows tracking for educational purposes
 - Provides information for all
- <http://web.facs.org/coc/default.htm>



53



Questions?



54



American Joint Committee on Cancer
Contact Information

Karen A. Pollitt – Manager

email: kpollitt@facs.org

phone: 312-202-5313

Donna M. Gress, RHIT, CTR – Technical Specialist

email: dgress@facs.org

phone: 312-202-5410

General Inquiries can be directed to AJCC@facs.org

AJCC Web Site

55 www.cancerstaging.org


